Fisher & Paykel Healthcare is a leading designer, manufacturer and marketer of a range of respiratory therapy solutions. Our products are sold into over 120 countries worldwide and our purpose is to improve care and outcomes through inspired and world-leading healthcare solutions. Optiflow™ Nasal High Flow has been well established in the critical care environment for over 20 years and its use outside of the ICU continues to expand.

Optiflow THRIVE™ is a unique airway management therapy used in general anaesthesia and procedural sedation cases. Optiflow THRIVE helps prevent desaturation1, clear CO21,2 and instils confidence in a time pressured environment1.

Optiflow™ Nasal High Flow is also used in the PACU environment using the same nasal interface for a care continuum. Optiflow Nasal High Flow significantly increases end-expiratory lung volume compared to low flow cannula4, helps prevent hypoxaemic events5 and helps reduce the escalation of care in some post-operative patients6.

References

1.Patel A, Nouraei S. Anaesthesia, 2015; 70(3):323-9 2. Gustafsson IM, Lodenius Å, Tunelli J, Ullman J, et al. Br J Anaesth. 2017;118(4):610-617 3. Groves N, Tobin A. Australian Critical Care, 2007; 20(4): 126-31 4. Corley A, Caruana L, Barnett A, et al. Br J Anaesth. 2011; 107(6): 998-1004 5. Maggiore S, Idone F, Vaschetto R, et al. Am J Respir Crit Care Med. 201; 190(3):282-8 6. Evans A, Groom P. CARE Convention, Coventry, 2017 [Abstract]

Legal text

Optiflow THRIVE, Optiflow and AIRVO2 are trademarks of Fisher & Paykel Healthcare Limited. For patent information, see fphcare.com/ip